Allogeneic iMP cells: Phase II data

The Phase II HeartCel trial in advanced heart failure patients at high risk of incomplete revascularization

Read the full 164 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE